Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study-Reference-Cited by-同舟云学术

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study

Published:2018-05-29 Issue:10 Volume:32 Page:1761-1767
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Ghazanfar M.N.¹,Holm J.G.¹,Thomsen S.F.¹²

Affiliation:

1. Department of Dermatology; Bispebjerg Hospital; Copenhagen Denmark

2. Department of Biomedical Sciences; University of Copenhagen; Copenhagen Denmark

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.15045/fullpdf

Reference36 articles.

1. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update;Zuberbier;Allergy,2018

2. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria;Maurer;N Engl J Med,2013

3. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy;Kaplan;J Allergy Clin Immunol,2013

4. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study;Saini;J Clin Invest Dermatol,2015

5. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase;Maurer;J Allergy Clin Immunol,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement;International Journal of Dermatology;2024-07-04

2. Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema;Journal of the European Academy of Dermatology and Venereology;2024-06-10

3. Role of patient-reported outcome measures in the management of chronic urticaria and angioedema;Indian Journal of Skin Allergy;2023-09-28

4. Clinical Response to Low-dose Omalizumab Treatment in Chronic Spontaneous Urticaria: A Retrospective Study of 179 Patients;Acta Dermato-Venereologica;2023-08-30

5. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria;International Journal of Molecular Sciences;2023-07-11